Subscribe To
Regenxbio reveals interim data from diabetic retinopathy gene therapy trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involve...
October 11, 2021, 1:25 pm
Regenxbio reveals interim data from diabetic retinopathy gene therapy trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involve...
October 11, 2021, 1:25 pm
Regenxbio reveals interim data from diabetic retinopathy gene therapy trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involve...
October 11, 2021, 1:25 pm
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am
Regenxbio presents positive initial data from phase ii altitude™ trial of rgx-314 for the treatment of diabetic retinopathy using suprachoroidal delivery at american society of retina specialists annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious...
October 9, 2021, 11:23 am